1015 – Long-Acting Cabotegravir/Rilpivirine in Pregnancy
Background Long-acting cabotegravir and rilpivirine (LA-CAB/RPV) is a novel injectable antiretroviral therapy approved for virologically suppressed individuals with HIV-1. Data on the safety, efficacy, and outcomes for individuals receiving LA-CAB/RPV during pregnancy are limited. We evaluated HIV viral suppression, perinatal, and neonatal outcomes in pregnant persons with HIV-1 receiving LA-CAB/RPV. This is the first case…